• Oncodesign Precision Medicine reported progress toward a Phase 1b study of Parkinson’s drug candidate OPM-201 planned for 2027.
• No new clinical results were presented; dose-setting work from the completed Phase 1 in healthy volunteers will be used to design Phase 1b.
• Manufacturing work produced initial tablet batches, supporting preparation of GMP supply for the Phase 1b trial.
• EMA’s CHMP validated the proposed long-term toxicology plan on July 23, 2026, supporting continued clinical development.
• An FDA pre-IND meeting request is being prepared; the IND filing is targeted for early 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncodesign Precision Medicine SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007727809) on October 07, 2026, and is solely responsible for the information contained therein.